A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma

Due to biological heterogeneity, lung adenocarcinoma (LUAD) patients with the same stage may exhibit variable responses to immunotherapy and a wide range of outcomes. It is urgent to seek a biomarker that can predict the prognosis and response to immunotherapy in these patients. In this study, we id...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Congkuan, Wu, Zhiquan, Wang, Qingwen, Wang, Yujin, Guo, Zixin, Li, Sheng, Hu, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875126/
https://www.ncbi.nlm.nih.gov/pubmed/33585490
http://dx.doi.org/10.3389/fcell.2021.634697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875126/
https://www.ncbi.nlm.nih.gov/pubmed/33585490
http://dx.doi.org/10.3389/fcell.2021.634697

Ejemplares similares